Alström syndrome is a rare inherited multisystem genetic disorder that affects several organs, including the eyes, ears, heart, pancreas, and endocrine system. One of the most significant and early manifestations of Alström syndrome is retinal dystrophy, which leads to progressive vision loss from childhood. This retinal degeneration occurs due to dysfunction and gradual loss of photoreceptor cells, especially cones and rods, resulting in severe visual impairment over time.
The first visual symptoms of Alström syndrome induced retinal dystrophy often appear in infancy or early childhood. These may include light sensitivity, involuntary eye movements (nystagmus), reduced visual clarity, and poor tracking of objects. As the condition progresses, patients experience worsening central vision, color vision defects, and gradual loss of peripheral vision. Many individuals develop legal blindness by adolescence or early adulthood.
The retinal degeneration in Alström syndrome is caused by mutations in the ALMS1 gene, which plays an important role in cellular structure, ciliary function, and intracellular signaling. Damage to photoreceptor cells disrupts the normal processing of visual information, leading to continuous decline in visual function. Since Alström syndrome affects multiple organ systems, patients may also experience hearing loss, obesity, insulin resistance, cardiomyopathy, and kidney dysfunction, making overall disease management complex.
Currently, there is no definitive cure for Alström syndrome or its associated retinal dystrophy. Conventional treatment focuses on visual rehabilitation, use of low-vision aids, tinted lenses for photophobia, and multidisciplinary medical care for systemic complications. While these strategies help patients adapt, they do not prevent ongoing retinal degeneration.
Stem cell therapy offers a regenerative approach aimed at supporting retinal health and slowing disease progression. At Eye Stem Cell Center, advanced regenerative protocols are designed to protect remaining photoreceptor cells, reduce oxidative stress, and enhance the retinal microenvironment. Stem cells release growth factors, neuroprotective molecules, and anti-inflammatory signals that help maintain retinal cell survival and improve tissue metabolism.
Although stem cell therapy cannot restore completely lost photoreceptors, it may help preserve existing retinal function and stabilize visual performance. The therapeutic objective is to delay further vision loss, improve contrast sensitivity, and enhance functional vision for daily activities such as reading, navigation, and digital use.
Before initiating treatment, patients undergo a detailed clinical assessment at Eye Stem Cell Center. This includes fundus examination, optical coherence tomography (OCT), electroretinography (ERG), visual field testing, and systemic health evaluation. Since Alström syndrome affects multiple organs, a multidisciplinary approach is followed to ensure patient safety and treatment suitability.
Treatment plans are fully personalized based on disease severity, age, current visual function, and overall medical condition. Patients are monitored closely throughout the therapy process with regular follow-up assessments to evaluate visual stability and functional improvement.
Stem cell therapy for Alström syndrome induced retinal dystrophy at Eye Stem Cell Center represents an advanced supportive option for patients facing progressive vision loss. By combining regenerative medicine with specialized ophthalmic and systemic care, the center focuses on preserving remaining vision, improving quality of life, and supporting long-term functional independence.
Alstrom Syndrome is a rare genetic disorder affecting vision, hearing, heart, and metabolism.
Vision loss usually starts in early childhood.
Cone-rod retinal dystrophy.
Regenerative therapy may support retinal cell survival and visual function.
Yes, symptoms worsen over time.